BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review

Stockholm, June 13, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST study evaluates exidavnemab, a drug candidate being developed as a treatment for Parkinson’s disease and Multiple System Atrophy (MSA).

The release as fetched from its publisher. bioarctic.com ↗